Related Experiment Video
Updated: Nov 13, 2025
Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeq™) postlicensure: a
Yuxiao Wang1, Jingxin Li2, Pinyuan Dai1
1School of Public Health, Southeast University, Nanjing, China.
Insights
The pentavalent rotavirus vaccine (RotaTeq™) shows 84% effectiveness against rotavirus gastroenteritis in real-world settings. Effectiveness is influenced by study design and socioeconomic status, particularly in high-income countries.
Area of Science:
- Vaccinology
- Pediatric Gastroenterology
- Public Health
Background:
- Rotavirus (RV) causes significant morbidity through RV-associated gastroenteritis (RVGE).
- Assessing the real-world effectiveness of the pentavalent RV vaccine (RotaTeq™) in children and infants is crucial.
Purpose of the Study:
- To evaluate the vaccine effectiveness (VE) of RotaTeq™ against RVGE in real-world settings.
- To perform a meta-analysis of existing studies to determine pooled VE.
Main Methods:
- Systematic literature search for peer-reviewed studies (Jan 2006 - May 2020).
- Meta-analysis to calculate pooled three-dose VE of RotaTeq™.
- Stratified analyses based on study design, population, SES, and RV strains.
Main Results:
- 28 studies included in the meta-analysis.
- Overall vaccine effectiveness (VE) estimated at 84% (95% CI, 80-87%).
- Study design and socioeconomic status significantly impacted VE; other factors showed minimal influence.
Conclusions:
- RotaTeq™ is effective against rotavirus infection, particularly in high-income countries.
- Optimizing study methodologies and expanding RV surveillance in low-income regions are vital for assessing real-world VE and improving vaccine strategies.
Background:
Rotavirus (RV), which causes RV-associated gastroenteritis (RVGE), has accounted for considerable morbidity. We aimed to assess the effectiveness (VE) of the oral pentavalent RV vaccine (RotaTeq™) in real-world settings in children and infants with gastroenteritis.
Methods:
We performed a systematic search for peer-reviewed studies published between 1 January 2006 and 1 May 2020 and a meta-analysis to calculate the VE of RotaTeq™ vaccine. The primary outcome was the pooled three-dose vaccine VE. Stratified analysis of the vaccine VEs was performed according to dosages, study design, population age, socioeconomic status (SES), introduction condition, control group types, outcomes of RV disease, and RV strains.
Results:
After screening 2359 unique records, 28 studies were included and meta-analyzed. The overall VE estimate was 84% (95% confidence interval [CI], 80-87%). Stratified analyses revealed a nonnegligible impact of factors such as study design and SES. Other factors did not show great impart to VE with no significant differences between groups.
Conclusions:
RotaTeq™ is effective against RV infection, especially in high-income countries. Adopting suitable study methods and expansion of RV surveillance in low-income regions is crucial to assess VE in real-life settings and provide feasible vaccine regimens to improve vaccine VE.
